Literature DB >> 24013383

Expression of the chemokine decoy receptor D6 is decreased in colon adenocarcinomas.

Veronica Langenes1, Helena Svensson, Lars Börjesson, Bengt Gustavsson, Mats Bemark, Åsa Sjöling, Marianne Quiding-Järbrink.   

Abstract

Recruitment of immune cells to tumors is a complex process crucial for both inflammation-driven tumor progression and specific anti-tumor cytotoxicity. Chemokines control the directed migration of immune cells, and their actions are partly controlled by nonsignaling chemokine decoy receptors. The role of the receptors such as D6, Duffy antigen receptor for chemokines and ChemoCentryx chemokine receptor in immunity to tumors is still unclear. Using real-time PCR, we detected significantly decreased expression of D6 mRNA in colon tumors compared to unaffected mucosa. D6 protein was expressed by lymphatic endothelium and mononuclear cells in the colon lamina propria and detected by immunohistochemistry in two out of six tissue samples containing high D6 mRNA levels, whereas no staining was observed in any tissue samples expressing low mRNA levels. When examining the density of lymphatic vessels in colon tumors, we detected a marked increase in vessels identified by the lymphatic endothelial marker Lyve-1, excluding passive regulation of D6 due to decreased lymphatic vessel density. In parallel, the Treg-recruiting chemokine CCL22, which is sequestered by D6, was threefold increased in tumor tissue. Furthermore, we could show that low D6 expression correlated to more invasive tumors and that tumor location influences D6 expression, which is lower in the more distal parts of the colon. The data support that regulation of D6 by colon tumors results in altered levels of proinflammatory CC chemokines, thereby shaping the local chemokine network to favor tumor survival. This may have implications for the design of future immunotherapy for colon cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24013383     DOI: 10.1007/s00262-013-1472-0

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  12 in total

Review 1.  The Role of Atypical Chemokine Receptor D6 (ACKR2) in Physiological and Pathological Conditions; Friend, Foe, or Both?

Authors:  Arezoo Gowhari Shabgah; Farhad Jadidi-Niaragh; Hamed Mohammadi; Farnoosh Ebrahimzadeh; Maziar Oveisee; Abbas Jahanara; Jamshid Gholizadeh Navashenaq
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

2.  Over-expression of Nav1.6 channels is associated with lymph node metastases in colorectal cancer.

Authors:  Shuiquan Lin; Yangbo Lv; Jianguang Xu; Xinglong Mao; Zhenhong Chen; Wuguang Lu
Journal:  World J Surg Oncol       Date:  2019-10-31       Impact factor: 2.754

3.  The chemokine scavenging receptor D6/ACKR2 is a target of miR-146a in thyroid cancer.

Authors:  Francesco Pacifico; Alessio Lepore; Stefano Mellone; Luca Sanguigno; Giorgia Federico; Adelaide Greco; Arturo Brunetti; Antonio Leonardi
Journal:  Genes Cancer       Date:  2017-05

4.  Inhibition of tumor formation and metastasis by a monoclonal antibody against lymphatic vessel endothelial hyaluronan receptor 1.

Authors:  Yuta Hara; Ryota Torii; Shiho Ueda; Erina Kurimoto; Eri Ueda; Hiroshi Okura; Yutaka Tatano; Hideki Yagi; Yoshiya Ohno; Toshiyuki Tanaka; Kazue Masuko; Takashi Masuko
Journal:  Cancer Sci       Date:  2018-08-26       Impact factor: 6.716

Review 5.  The Interplay Between Lymphatic Vessels and Chemokines.

Authors:  Rae H Farnsworth; Tara Karnezis; Simon J Maciburko; Scott N Mueller; Steven A Stacker
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

Review 6.  CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4.

Authors:  Jan Korbecki; Klaudyna Kojder; Donata Simińska; Romuald Bohatyrewicz; Izabela Gutowska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

Review 7.  A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy.

Authors:  Gizem Duru; Marjolein van Egmond; Niels Heemskerk
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

Review 8.  CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands.

Authors:  Jan Korbecki; Szymon Grochans; Izabela Gutowska; Katarzyna Barczak; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

9.  Biphasic Expression of Atypical Chemokine Receptor (ACKR) 2 and ACKR4 in Colorectal Neoplasms in Association with Histopathological Findings.

Authors:  Paulina Lewandowska; Jaroslaw Wierzbicki; Marek Zawadzki; Anil Agrawal; Małgorzata Krzystek-Korpacka
Journal:  Biomolecules       Date:  2020-12-23

10.  Cytokine decoy and scavenger receptors as key regulators of immunity and inflammation.

Authors:  Raffaella Bonecchi; Cecilia Garlanda; Alberto Mantovani; Federica Riva
Journal:  Cytokine       Date:  2016-08-04       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.